Patient-facing drug information for ANKTIVA, including its use with BCG for BCG-unresponsive NMIBC with CIS with or without papillary tumors.
ANKTIVA (N-803) Plus BCG for BCG-Unresponsive NMIBC
ANKTIVA (N-803) Plus BCG for BCG-Unresponsive NMIBC is a conventional oncology treatment or care pathway used within standard cancer care, usually under the direction of oncology specialists and with disease-specific indications. In cancer care, it should be evaluated by evidence level, intended use, safety, interactions, and whether it is being used as conventional treatment, supportive care, an experimental adjunct.
FDA approval-summary article reviewing the data and benefit-risk reasoning for N-803 plus BCG in BCG-unresponsive NMIBC with CIS.
CancerNetwork approval alert noting nogapendekin alfa-inbakicept with BCG approval in BCG-unresponsive NMIBC.
FDA approval notice for nogapendekin alfa inbakicept-pmln (ANKTIVA) with BCG in adult patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors.
Plain-language summary of N-803 plus BCG clinical study.
AP report on FDA warning over misleading promotional claims for ANKTIVA TV ad and podcast.
Publication/source summary on N-803 plus BCG in BCG-unresponsive NMIBC.